Table 2.
Cumulative incidence of BCRL diagnosis by patient and clinical factors among breast cancer patients undergoing axillary staging surgery (n = 1512)
| N | 2-year Cumulative Incidence | Lower 95% CI |
Upper 95% CI |
5-year Cumulative Incidence | Lower 95% CI |
Upper 95% CI |
|
|---|---|---|---|---|---|---|---|
| BMI category | |||||||
| Underweight or Normal weight (BMI<25) | 845 | 5.7% | 4.3% | 7.4% | 8.0% | 6.3% | 10.0% |
| Overweight (BMI 25–29.99) | 399 | 11.1% | 8.2% | 14.4% | 14.4% | 11.2% | 18.1% |
| Obese (BMI 30–34.99) | 187 | 10.8% | 6.8% | 15.7% | 13.0% | 8.6% | 18.3% |
| Morbidly obese (BMI≥35) | 76 | 15.8% | 8.6% | 24.9% | 17.1% | 9.6% | 26.5% |
| Pathologic stage | |||||||
| 0 | 121 | 3.3% | 1.1% | 7.7% | 4.2% | 1.6% | 8.9% |
| I | 769 | 2.9% | 1.9% | 4.2% | 5.4% | 3.9% | 7.1% |
| II | 496 | 11.8% | 9.1% | 14.8% | 14.1% | 11.1% | 17.3% |
| III | 126 | 32.0% | 24.0% | 40.3% | 37.8% | 29.3% | 46.3% |
| Surgery combination | |||||||
| BCS with SLN | 450 | 5.4% | 3.5% | 7.7% | 6.0% | 4.1% | 8.5% |
| Mastectomy with SLN | 276 | 2.9% | 1.4% | 5.4% | 4.0% | 2.1% | 6.8% |
| BCS with ALND | 357 | 9.6% | 6.8% | 12.9% | 14.7% | 11.2% | 18.6% |
| Mastectomy with ALND | 429 | 13.6% | 10.5% | 17.0% | 17.0% | 13.6% | 20.7% |
| Radiation therapy | |||||||
| None | 621 | 4.2% | 2.8% | 6.0% | 5.9% | 4.2% | 7.9% |
| Breast or chest wall only | 652 | 5.4% | 3.8% | 7.3% | 8.0% | 6.1% | 10.3% |
| Nodal (± breast or chest wall) | 239 | 26.6% | 21.1% | 32.3% | 31.3% | 25.5% | 37.3% |
| Chemotherapy group | |||||||
| AC+Taxane | 250 | 23.4% | 18.3% | 28.8% | 27.2% | 21.8% | 32.9% |
| AC without Taxane | 195 | 9.8% | 6.1% | 14.5% | 13.5% | 9.1% | 18.7% |
| Taxane without AC | 24 | 20.8% | 7.4% | 39.0% | 29.7% | 12.8% | 48.8% |
| Other agents | 45 | 4.6% | 0.8% | 13.8% | 6.9% | 1.7% | 17.0% |
| No chemotherapy | 998 | 4.0% | 2.9% | 5.4% | 6.0% | 4.6% | 7.6% |
| Treatment combination* | |||||||
| SLN only | 220 | 2.7% | 1.1% | 5.6% | 4.1% | 2.0% | 7.4% |
| SLN & breast or chest wall RT only | 312 | 4.5% | 2.6% | 7.2% | 4.8% | 2.8% | 7.6% |
| ALND only | 233 | 1.7% | 0.6% | 4.1% | 3.5% | 1.6% | 6.4% |
| ALND & breast or chest wall RT only | 191 | 4.2% | 2.0% | 7.7% | 9.5% | 5.8% | 14.2% |
| ALND & nodal (± breast or chest wall) RT | 26 | 23.1% | 9.1% | 40.7% | 26.9% | 11.6% | 44.9% |
| ALND & AC+T chemotherapy | 36 | 30.6% | 16.4% | 46.0% | 33.6% | 18.7% | 49.3% |
| ALND & AC w/o Taxane chemotherapy | 49 | 4.2% | 0.7% | 12.7% | 8.4% | 2.6% | 18.5% |
| ALND & breast or chest wall only RT & AC+T chemotherapy | 24 | 25.0% | 9.9% | 43.6% | 33.9% | 15.7% | 53.2% |
| ALND & breast or chest wall only RT & AC w/o Taxane chemotherapy | 32 | 3.1% | 0.2% | 14.0% | 6.4% | 1.1% | 18.7% |
| ALND & nodal (± breast or chest wall) RT & AC+T chemotherapy | 110 | 35.0% | 26.1% | 44.0% | 39.7% | 30.4% | 48.8% |
| ALND & nodal (± breast or chest wall) RT & AC w/o Taxane chemotherapy | 41 | 22.0% | 10.7% | 35.7% | 29.3% | 16.2% | 43.7% |
*
Only common treatment combinations with sufficient numbers of patients for estimation were included in this table.